Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

August 29, 2023 by Alan Khadavi

Dupixent for COPD, a new indication

Dupixent for COPD is currently being studied and seeking an approval for this new indication. Type 2 inflammation is present in a significant portion of patients with COPD and it increases the exacerbation risk.

A recent study published in the New England Journal of Medicine performed a randomized, placebo controlled phase 3 trial to investigate the efficacy of Dupixent, a monoclonal antibody that inhibits the signaling of both IL-4 and IL-13 in symptomatic patients with COPD with a blood eosinophil count of at least 300 per microliter.

The results showed that Dupixent (dupilumab) decreased the rate of exacerbations, improved lung function, quality of life and symptom control. These effects were see within 4 weeks of treatment initiation and remained in effect for the year of treatment.

This has showed that for patients with COPD, defining if they are of the TH2 variety with elevated eosinophils, Dupixent may be a treatment for them. This simple blood test can given a more personalized approach to those who have COPD.

Dupixent currently has several other indications:

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

Dupixent (Dupilumab) for Atopic Dermatitis/Eczema

Best Nasal Polyps Treatment

Dupilumab for Asthma, a New Indication

and it is also working on an urticaria indication as well, Dupixent for Hives

Currently there are very limited options for patients with COPD besides several types of inhalers. Inhaled Triple Therapy for Respiratory Disease

Dupixent for COPD may be an option for patients who meet the criteria who have type 2 inflammation with elevated eosinophils above 300 which can be seen from a simple blood test, CBC with a differential.

If you have COPD and are not well controlled, speak to your doctor and if your eosinophil count is above 300, you may be candidate for Dupixent when it becomes FDA approved.

Conditions We Treat and Procedures

Spiriva Respimat for Add-on Asthma

 

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page